Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05859854
Other study ID # 153(A)IM21348
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 24, 2023
Est. completion date September 30, 2025

Study information

Verified date May 2023
Source Aziende Chimiche Riunite Angelini Francesco S.p.A
Contact Valentina Villano, MD
Phone +390691045340
Email valentina.villano@angelinipharma.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The BLESS Study contributes to filling this information gap by collecting data from the Italian clinical practice and the Compassionate Use Program, to better characterize the clinical profile of cenobamate describing its effectiveness, safety and tolerability in adult patients diagnosed with uncontrolled focal epilepsy despite the use of at least two antiepileptic medicinal products.


Description:

The main objective of the study is to describe the effectiveness of adjunctive cenobamate treatment in adult patients with uncontrolled focal epilepsy in Italy, overall and according to age class, setting of cenobamate treatment, cenobamate final target daily dose prescribed, and number of concomitant Anti Seizure Medications (ASMs). This will be assessed by intra-patient percent change and achievement of a ≥50% reduction in the seizure frequency from the pre-treatment baseline over a period of 52 weeks.


Recruitment information / eligibility

Status Recruiting
Enrollment 1200
Est. completion date September 30, 2025
Est. primary completion date September 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: - Age =18 years at the time of cenobamate treatment initiation - Male or female patients - Patients diagnosed with focal epilepsy uncontrolled despite a history of treatment with at least two antiepileptic medicinal products at the time of cenobamate treatment initiation in agreement with the Summary of Product Characteristics (SmPC) - Patients who at enrolment had received at least 12 weeks (titration period up to the initial recommended target dose of 200 mg daily completed) but no more than 52 weeks of cenobamate as adjunctive treatment of focal-onset seizures with or without secondary generalization - Patients with available retrospective data in medical charts and seizure diaries, including information about baseline seizure frequency prior to cenobamate treatment initiation - Patients who gave written informed consent to take part into the study and personal data processing consent following local regulation. - Patients who received adjunctive cenobamate for at least 12 weeks and discontinued permanently treatment before enrolment will also be included in the study- Exclusion Criteria: - Patients diagnosed with familial short-QT syndrome - Patients affected by hypersensitivity to the active substance cenobamate or to any of the excipients (e.g., lactose monohydrate) - Patients with history of severe drug-induced hypersensitivity reaction, including (but not limited to) drug reaction with eosinophilia and systemic symptoms (DRESS), and Stevens Johnson syndrome - Patients enrolled in a clinical trial in which treatments for epilepsy are managed through a study protocol - Patient unable to read and write in Italian language and to autonomously fill in questionnaires and scales - Patients with a known pregnancy or who are breast-feeding from cenobamate treatment initiation till enrolment visit.

Study Design


Locations

Country Name City State
Italy Policlinico di Bari Bari
Italy Università degli Studi di Catanzaro "Magna Graecia" Catanzaro
Italy Associazione La Nostra Famiglia - IRCCS Eugenio Medea Conegliano Treviso
Italy Fondazione Istituto Neurologico Casimiro Mondino Pavia
Italy IRCCS Neuromed Pozzilli Isernia
Italy Campus Bio-Medico Roma
Italy Policlinico Umberto I Roma
Italy Humanitas Gradenigo Torino
Italy Azienda Sanitaria Universitaria (A.O.U.) Integrata Udine
Italy Ospedale San Bortolo Vicenza

Sponsors (2)

Lead Sponsor Collaborator
Aziende Chimiche Riunite Angelini Francesco S.p.A Iqvia Pty Ltd

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Absolute frequency of patients achieving a 50 % or greater reduction in the seizure frequency (overall) Seizure frequency during the baseline and post-baseline assessments was calculated by summing the total number of seizures (all types of seizures) reported in each considered period and dividing by the duration of that period (number of days), excluding days with no available diary data, and multiplying by 28 to normalize to a monthly rate ("monthly seizure frequency"). 12, 24 and 52 weeks of cenobamate treatment initiation
Primary Relative frequency of patients achieving a =50% (50% or greater) reduction in the seizure frequency (overall) Seizure frequency during the baseline and post-baseline assessments was calculated by summing the total number of seizures (all types of seizures) reported in each considered period and dividing by the duration of that period (number of days), excluding days with no available diary data, and multiplying by 28 to normalize to a monthly rate ("monthly seizure frequency"). 12, 24 and 52 weeks of cenobamate treatment initiation
Primary Intra-patient percent change in the seizure frequency (overall) Intra-patient percent change from baseline will be defined as [(monthly seizure frequency at post-baseline assessments - monthly seizure frequency at baseline), divided by the monthly seizure frequency at baseline] multiplied by 100. 12, 24 and 52 weeks of cenobamate treatment initiation
Primary Absolute frequency of patients achieving a 50 % or greater reduction in the seizure (stratified) Seizure frequency during the baseline and post-baseline assessments was calculated by summing the total number of seizures (all types of seizures) reported in each considered period and dividing by the duration of that period (number of days), excluding days with no available diary data, and multiplying by 28 to normalize to a monthly rate ("monthly seizure frequency").
Population will be stratified according to the following:
Age class of patient at the time of cenobamate treatment initiation (i.e., <65 years; =65 years).
Setting of cenobamate treatment initiation (i.e., CUP; current clinical practice).
Cenobamate final target daily dose prescribed (i.e., 200 mg; >200 mg).
Number of ASMs concomitant with cenobamate (i.e., =2 ASMs; >2 ASMs).
12, 24 and 52 weeks of cenobamate treatment initiation
Primary Relative frequency of patients achieving a =50% (50% or greater) reduction in the seizure frequency (stratified) Seizure frequency during the baseline and post-baseline assessments was calculated by summing the total number of seizures (all types of seizures) reported in each considered period and dividing by the duration of that period (number of days), excluding days with no available diary data, and multiplying by 28 to normalize to a monthly rate ("monthly seizure frequency").
Population will be stratified according to the following:
Age class of patient at the time of cenobamate treatment initiation (i.e., <65 years; =65 years).
Setting of cenobamate treatment initiation (i.e., CUP; current clinical practice).
Cenobamate final target daily dose prescribed (i.e., 200 mg; >200 mg).
Number of ASMs concomitant with cenobamate (i.e., =2 ASMs; >2 ASMs).
12, 24 and 52 weeks of cenobamate treatment initiation
Primary Intra-patient percent change in the seizure frequency (stratified) Intra-patient percent change from baseline will be defined as [(monthly seizure frequency at post-baseline assessments - monthly seizure frequency at baseline), divided by the monthly seizure frequency at baseline] multiplied by 100.
Population will be stratified according to the following:
Age class of patient at the time of cenobamate treatment initiation (i.e., <65 years; =65 years).
Setting of cenobamate treatment initiation (i.e., CUP; current clinical practice).
Cenobamate final target daily dose prescribed (i.e., 200 mg; >200 mg).
Number of ASMs concomitant with cenobamate (i.e., =2 ASMs; >2 ASMs).
12, 24 and 52 weeks of cenobamate treatment initiation
Secondary Absolute frequency of patients achieving a =50%/=75%/=90%/=100% sustained reduction in the seizure frequency Sustained seizure frequency reduction will be defined as a =50%/=75%/=90%/=100% reduction in baseline seizure frequency achieved at 12 weeks of cenobamate treatment initiation, that continues (is sustained) without interruption and without cenobamate permanent discontinuation through the observation period until 24 and 52 weeks of cenobamate treatment initiation, respectively. 24 and 52 weeks of cenobamate treatment initiation.
Secondary Absolute frequency of patients achieving a =75%/=90%/=100% reduction in the seizure frequency Seizure frequency reduction will be defined as a =75%/=90%/=100% reduction in baseline seizure frequency achieved at 12, 24 and 52 weeks of cenobamate treatment initiation, respectively. 12, 24 and 52 weeks of cenobamate treatment initiation.
Secondary Relative frequencies of patients achieving a =50%/=75%/=90%/=100% sustained reduction in the seizure frequency Sustained seizure frequency reduction will be defined as a =50%/=75%/=90%/=100% reduction in baseline seizure frequency achieved at 12 weeks of cenobamate treatment initiation, that continues (is sustained) without interruption and without cenobamate permanent discontinuation through the observation period until 24 and 52 weeks of cenobamate treatment initiation, respectively 24 and 52 weeks of cenobamate treatment initiation.
Secondary Relative frequencies of patients achieving a =75%/=90%/=100% reduction in the seizure frequency Seizure frequency reduction will be defined as a =75%/=90%/=100% reduction in baseline seizure frequency achieved at 12, 24 and 52 weeks of cenobamate treatment initiation. 12, 24 and 52 weeks of cenobamate treatment initiation.
Secondary Absolute frequency of patients with at least one AE Absolute frequency of patients treated with cenobamate who experienced at least one AE during the applicable observation period Through study completion, an average of 1 year
Secondary Relative frequency of patients with at least one AE Relative frequency of patients treated with cenobamate who experienced at least one AE during the applicable observation period Through study completion, an average of 1 year
Secondary Absolute frequency of patients with at least one ADR Absolute frequency of patients treated with cenobamate who experienced at least one ADR during the applicable observation period Through study completion, an average of 1 year
Secondary Relative frequency of patients with at least one ADR Relative frequency of patients treated with cenobamate who experienced at least one ADR during the applicable observation period Through study completion, an average of 1 year
Secondary Absolute frequency of patients treated with at least one SAE Absolute frequency of patients treated with at least one SAE during the applicable observation period Through study completion, an average of 1 year
Secondary Relative frequency of patients treated with at least one SAE Relative frequency of patients treated with at least one SAE during the applicable observation period Through study completion, an average of 1 year
Secondary Health-Related Quality of life (HRQoL) The Health-Related Quality of life (HRQoL) of patients will be assessed by means of the 31-item Quality Of Life In Epilepsy inventory (QOLIE-31).
The 31-item Quality Of Life In Epilepsy inventory (QOLIE-31) is a patient self-reported instrument that contains 31 items grouped in seven multi-item scales ( "seizure worry", "overall QoL", "emotional well-being", "energy fatigue", "cognitive functioning", "medication effects" and "social functioning"). Different items in the QOLIE-31 have different ranges of precoded numeric values, so the scoring procedure requires conversion from raw, precoded numeric values to scores of 0-100 points, with higher scores reflecting better quality of life. The QOLIE-31 overall score is calculated by summing the product of each scale score times its weight and summing over all scales, according to the instructions obtained from copyright holders.
12, 24 and 52 weeks
Secondary Patient Global functioning (CGI-S) The patient global functioning will be assessed by means of the Clinical Global Impression (CGI) Scales. The Early Clinical Drug Evaluation Program (ECDEU) version of the CGI is a 3-item clinician rated scale that measures illness severity (CGI-S), global improvement or change (CGI-I) and treatment response (efficacy index: CGI-E).
The CGI-S score ranges from 1 (normal) through to 7 (amongst the most severely ill patients).
The calculation of the scores will be performed according to the instructions obtained from copyright holders.
12, 24 and 52 weeks
Secondary Patient Global functioning (CGI-I) The patient global functioning will be assessed by means of the Clinical Global Impression (CGI) Scales. The Early Clinical Drug Evaluation Program (ECDEU) version of the CGI is a 3-item clinician rated scale that measures illness severity (CGI-S), global improvement or change (CGI-I) and treatment response (efficacy index: CGI-E).
The CGI-I score ranges from 1 (very much improved) through to 7 (very much worse).
The calculation of the scores will be performed according to the instructions obtained from copyright holders.
12, 24 and 52 weeks
Secondary Patient Global functioning (CGI-E) The patient global functioning will be assessed by means of the Clinical Global Impression (CGI) Scales. The Early Clinical Drug Evaluation Program (ECDEU) version of the CGI is a 3-item clinician rated scale that measures illness severity (CGI-S), global improvement or change (CGI-I) and treatment response (efficacy index: CGI-E).
The CGI-E score should take account of both therapeutic effect and tolerance, and ranges from 0 (marked improvement and no toxicity) and 4 (unchanged or worse and toxicity outweigh the therapeutic effects). Each component of the CGI is rated separately; the instrument does not yield a global score.
The calculation of the scores will be performed according to the instructions obtained from copyright holders.
12, 24 and 52 weeks
Secondary Daytime Sleepiness Daytime Sleepiness will be assessed by means of the Epworth Sleepiness Scale (ESS). The ESS is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different daily activities. The ESS score can range from 0 to 24. The higher the ESS score, the higher that person Average Sleep Propensity in Daily Life (ASP), or their daytime sleepiness across a wide range of activities in their daily lives. 12, 24 and 52 weeks
Secondary Hospital Anxiety and Depression Anxiety and depression symptoms will be assessed by means of the the Hospital Anxiety and Depression Scale (HADS). This is a patient self-reported instrument consisting of 14 items that provide scores on two specific subscales: "Anxiety" subscale (HADS-A, 7 items) and "Depression" subscale (HADS-D, 7 items).
All items were scored on a 4-point Likert scale from 0 ("never") to 3 ("almost every day") referring to overt symptoms within the last week. Total scores range from 0 to 21 points for each subscale, with higher scores indicating higher levels of symptoms.
12, 24 and 52 weeks
Secondary Retention with cenobamate Retention with cenobamate will be assessed by calculating the frequency of patients still on treatment with cenobamate at 52 weeks of treatment initiation. 52 weeks
See also
  Status Clinical Trial Phase
Completed NCT04595513 - Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants Phase 1/Phase 2
Completed NCT02909387 - Adapting Project UPLIFT for Blacks in Georgia N/A
Completed NCT05552924 - Self Acupressure on Fatigue and Sleep Quality in Epilepsy Patients N/A
Terminated NCT01668654 - Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS Phase 3
Not yet recruiting NCT05068323 - Impact of Interictal Epileptiform Activity on Some Cognitive Domains in Newly Diagnosed Epileptic Patients N/A
Completed NCT03994718 - Creative Arts II Study N/A
Recruiting NCT04076449 - Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy
Completed NCT00782249 - Trial Comparing Different Stimulation Paradigms in Patients Treated With Vagus Nerve Stimulation for Refractory Epilepsy N/A
Completed NCT03683381 - App-based Intervention for Treating Insomnia Among Patients With Epilepsy N/A
Recruiting NCT05101161 - Neurofeedback Using Implanted Deep Brain Stimulation Electrodes N/A
Active, not recruiting NCT06034353 - Impact of Pharmacist-led Cognitive Behavioral Intervention on Adherence and Quality of Life of Epileptic Patients N/A
Recruiting NCT05769933 - Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
Not yet recruiting NCT06408428 - Glioma Intraoperative MicroElectroCorticoGraphy N/A
Not yet recruiting NCT05559060 - Comorbidities of Epilepsy(Cognitive and Psychiatric Dysfunction)
Completed NCT02977208 - Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use Phase 4
Completed NCT02646631 - Behavioral and Educational Tools to Improve Epilepsy Care N/A
Completed NCT02952456 - Phenomenological Approach of Epilepsy in Patients With Epilepsy
Recruiting NCT02539134 - TAK-935 Multiple Rising Dose Study in Healthy Participants Phase 1
Terminated NCT02757547 - Transcranial Magnetic Stimulation for Epilepsy N/A
Completed NCT02491073 - Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL) N/A